• Inositec AG Secures CHF1.4 million in Seed Financing to Advance New Class of Inositol Hexaphosphate-Based Drug Candidates

    Lead programs address unmet medical needs in vascular calcification and C. difficile infection Zurich, Switzerland, 27th October 2016 – Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the closing of a … Continue reading

    Posted in Press Release | Leave a comment